Non-alcoholic Fatty Liver in the Pathogenesis of Diabetes

  • Cristiane A. Villela Nogueira
  • Nathalie Carvalho Leite


Non-alcoholic fatty liver disease [1] is prevalent worldwide and is recently one of the leading causes of chronic liver disease in the occident due to obesity-related epidemic and metabolic syndrome [2]. NAFLD presents with different phenotypes and may progress to cirrhosis and hepatocellular carcinoma. Moreover, it may be the leading cause for liver transplant in the next decade [3]. NAFLD was formerly identified in 1980, when Ludwig et al. described a small series of patients with liver histology characterized by fat accumulation, hepatic necroinflammation, and, in most cases, fibrosis, in the absence of a history of excessive alcohol consumption [4].


Non-alcoholic fatty liver Steatosis Steatohepatitis Cirrhosis Hepatocellular carcinoma Fibrosis scores 


  1. 1.
    Piscaglia F, Svegliati-Baroni G, Barchetti A, et al. Clinical patterns of hepatocellular carcinoma in nonalcoholic fatty liver disease: a multicenter prospective study. Hepatology (Baltimore, Md). 2016;63:827–38.CrossRefGoogle Scholar
  2. 2.
    Rinella ME. Nonalcoholic fatty liver disease: a systematic review. JAMA. 2015;313:2263–73.CrossRefGoogle Scholar
  3. 3.
    Wong RJ, Aguilar M, Cheung R, et al. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. Gastroenterology. 2015;148:547–55.CrossRefGoogle Scholar
  4. 4.
    Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc. 1980;55:434–8.PubMedGoogle Scholar
  5. 5.
    Kleiner D, Brunt E. Nonalcoholic fatty liver disease: pathologic patterns and biopsy evaluation in clinical research. Semin Liver Dis. 2012;32:3–13.CrossRefGoogle Scholar
  6. 6.
    Browning JD, Szczepaniak LS, Dobbins R, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology (Baltimore, Md). 2004;40:1387–95.CrossRefGoogle Scholar
  7. 7.
    Loomba R, Sanyal AJ. The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol. 2013;10:686.CrossRefGoogle Scholar
  8. 8.
    Hoofnagle JH, Van Natta ML, Kleiner DE, et al. Vitamin E and changes in serum alanine aminotransferase levels in patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2013;38:134–43.CrossRefGoogle Scholar
  9. 9.
    Babusik P, Bilal M, Duris I. Nonalcoholic fatty liver disease of two ethnic groups in Kuwait: comparison of prevalence and risk factors. Med Princ Pract. 2012;21:56–62.CrossRefGoogle Scholar
  10. 10.
    Mendez-Sanchez N. Non alcoholic fatty liver disease. Ann Hepatol. 2009;8(Suppl 1):S3.CrossRefGoogle Scholar
  11. 11.
    Onyekwere CA, Ogbera AO, Balogun BO. Non-alcoholic fatty liver disease and the metabolic syndrome in an urban hospital serving an African community. Ann Hepatol. 2011;10:119–24.CrossRefGoogle Scholar
  12. 12.
    Bellentani S, Scaglioni F, Marino M, Bedogni G. Epidemiology of non-alcoholic fatty liver disease. Dig Dis. 2010;28:155–61.CrossRefGoogle Scholar
  13. 13.
    Leite N, Salles G, Araujo A, Villela-Nogueira C, Cardoso C. Prevalence and associated factors of non-alcoholic fatty liver disease in patients with type-2 diabetes mellitus. Liver Int. 2009;29:113–9.CrossRefGoogle Scholar
  14. 14.
    Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care. 2003;26(Suppl 1):S5–20.Google Scholar
  15. 15.
    Williamson RM, Price JF, Glancy S, et al. Prevalence of and risk factors for hepatic steatosis and nonalcoholic fatty liver disease in people with type 2 diabetes: the Edinburgh type 2 diabetes study. Diabetes Care. 2011;34:1139–44.CrossRefGoogle Scholar
  16. 16.
    Sanyal A, Poklepovic A, Moyneur E, Barghout V. Population-based risk factors and resource utilization for HCC: US perspective. Curr Med Res Opin. 2010;26:2183–91.CrossRefGoogle Scholar
  17. 17.
    Charlton M, Burns J, Pedersen R, Watt K, Heimbach J, Dierkhising R. Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. Gastroenterology. 2011;141:1249–53.CrossRefGoogle Scholar
  18. 18.
    Saadeh S, Younossi ZM, Remer EM, et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology. 2002;123:745–50.CrossRefGoogle Scholar
  19. 19.
    Alberti KG, Zimmet P, Shaw J, IDF Epidemiology Task Force Consensus Group. The metabolic syndrome--a new worldwide definition. Lancet. 2005;366:1059–62.CrossRefGoogle Scholar
  20. 20.
    Jeanes YM, Reeves S. Metabolic consequences of obesity and insulin resistance in polycystic ovary syndrome: diagnostic and methodological challenges. Nutr Res Rev. 2017;30(1):97–105.CrossRefGoogle Scholar
  21. 21.
    Angulo P. Nonalcoholic fatty liver disease. N Engl J Med. 2002;346:1221–31.CrossRefGoogle Scholar
  22. 22.
    Osman KA, Osman MM, Ahmed MH. Tamoxifen-induced non-alcoholic steatohepatitis: where are we now and where are we going? Expert Opin Drug Saf. 2007;6:1–4.CrossRefGoogle Scholar
  23. 23.
    Farrell GC. Drugs and steatohepatitis. Semin Liver Dis. 2002;22:185–94.CrossRefGoogle Scholar
  24. 24.
    Debongnie JC, Pauls C, Fievez M, Wibin E. Prospective evaluation of the diagnostic accuracy of liver ultrasonography. Gut. 1981;22:130–5.CrossRefGoogle Scholar
  25. 25.
    Scaglioni F, Ciccia S, Marino M, Bedogni G, Bellentani S. ASH and NASH. Dig Dis. 2011;29:202–10.CrossRefGoogle Scholar
  26. 26.
    Liangpunsakul S, Chalasani N. What should we recommend to our patients with NAFLD regarding alcohol use? Am J Gastroenterol. 2012;107:976–8.CrossRefGoogle Scholar
  27. 27.
    Pendino GM, Mariano A, Surace P, et al. Prevalence and etiology of altered liver tests: a population-based survey in a Mediterranean town. Hepatology (Baltimore, Md). 2005;41:1151–9.CrossRefGoogle Scholar
  28. 28.
    Abdelmalek MF, Sanderson SO, Angulo P, et al. Betaine for nonalcoholic fatty liver disease: results of a randomized placebo-controlled trial. Hepatology. 2009;50:1818–26.CrossRefGoogle Scholar
  29. 29.
    Sorrentino P, Tarantino G, Conca P, et al. Silent non-alcoholic fatty liver disease-a clinical-histological study. J Hepatol. 2004;41:751–7.CrossRefGoogle Scholar
  30. 30.
    Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352:854–65.Google Scholar
  31. 31.
    McPherson S, Stewart SF, Henderson E, Burt AD, Day CP. Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease. Gut. 2010;59:1265–9.CrossRefGoogle Scholar
  32. 32.
    Bedossa P. Pathology of non-alcoholic fatty liver disease. Liver Int. 2017;37(Suppl 1):85–9.CrossRefGoogle Scholar
  33. 33.
    Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 2001;285:2486–97.CrossRefGoogle Scholar
  34. 34.
    de Ledinghen V, Wong VW, Vergniol J, et al. Diagnosis of liver fibrosis and cirrhosis using liver stiffness measurement: comparison between M and XL probe of FibroScan(R). J Hepatol. 2012;56:833–9.CrossRefGoogle Scholar
  35. 35.
    Wong VW, Vergniol J, Wong GL, et al. Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. Hepatology (Baltimore, Md). 2010;51:454–62.CrossRefGoogle Scholar
  36. 36.
    Samir AE, Dhyani M, Vij A, et al. Shear-wave elastography for the estimation of liver fibrosis in chronic liver disease: determining accuracy and ideal site for measurement. Radiology. 2015;274:888–96.CrossRefGoogle Scholar
  37. 37.
    Cassinotto C, Lapuyade B, Mouries A, et al. Non-invasive assessment of liver fibrosis with impulse elastography: comparison of Supersonic Shear Imaging with ARFI and FibroScan(R). J Hepatol. 2014;61:550–7.CrossRefGoogle Scholar
  38. 38.
    Younossi Z, Gramlich T, Matteoni C, Boparai N, Mccullough A. Nonalcoholic fatty liver disease in patients with type 2 diabetes. Clin Gastroenterol Hepatol. 2004;2:262–5.CrossRefGoogle Scholar
  39. 39.
    Prashanth M, Ganesh HK, Vima MV, et al. Prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus. J Assoc Physicians India. 2009;57:205–10.PubMedGoogle Scholar
  40. 40.
    Leite N, Villela-Nogueira C, Pannain V, et al. Histopathological stages of nonalcoholic fatty liver disease in type 2 diabetes: prevalences and correlated factors. Liver Int. 2011;31:700–6.CrossRefGoogle Scholar
  41. 41.
    Loomba R, Abraham M, Unalp A, et al. Association between diabetes, family history of diabetes, and risk of nonalcoholic steatohepatitis and fibrosis. Hepatology (Baltimore, Md). 2012;56:943–51.CrossRefGoogle Scholar
  42. 42.
    Targher G, Bertolini L, Padovani R, et al. Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care. 2007;30:1212–8.CrossRefGoogle Scholar
  43. 43.
    Targher G, Bertolini L, Padovani R, et al. Prevalence of non-alcoholic fatty liver disease and its association with cardiovascular disease in patients with type 1 diabetes. J Hepatol. 2010;53:713–8.CrossRefGoogle Scholar
  44. 44.
    Targher G, Bertolini L, Rodella S, Lippi G, Zoppini G, Chonchol M. Relationship between kidney function and liver histology in subjects with nonalcoholic steatohepatitis. Clin J Am Soc Nephrol. 2010;5:2166–71.CrossRefGoogle Scholar
  45. 45.
    Targher G, Chonchol M, Pichiri I, Zoppini G. Risk of cardiovascular disease and chronic kidney disease in diabetic patients with non-alcoholic fatty liver disease: just a coincidence? J Endocrinol Investig. 2011;34:544–51.Google Scholar
  46. 46.
    Ortiz-Lopez C, Lomonaco R, Orsak B, et al. Prevalence of prediabetes and diabetes and metabolic profile of patients with nonalcoholic fatty liver disease (NAFLD). Diabetes Care. 2012;35:873–8.CrossRefGoogle Scholar
  47. 47.
    Willner I, Waters B, Patil S, Reuben A, Morelli J, Riely C. Ninety patients with nonalcoholic steatohepatitis: insulin resistance, familial tendency, and severity of disease. Am J Gastroenterol. 2001;96:2957–61.CrossRefGoogle Scholar
  48. 48.
    Kasturiratne A, Weerasinghe S, Dassanayake AS, et al. Influence of non-alcoholic fatty liver disease on the development of diabetes mellitus. J Gastroenterol Hepatol. 2013;28:142–7.CrossRefGoogle Scholar
  49. 49.
    Choi JH, Rhee EJ, Bae JC, et al. Increased risk of type 2 diabetes in subjects with both elevated liver enzymes and ultrasonographically diagnosed nonalcoholic fatty liver disease: a 4-year longitudinal study. Arch Med Res. 2013;44:115–20.CrossRefGoogle Scholar
  50. 50.
    Shah RV, Allison MA, Lima JA, et al. Liver fat, statin use, and incident diabetes: the multi-ethnic study of atherosclerosis. Atherosclerosis. 2015;242:211–7.CrossRefGoogle Scholar
  51. 51.
    Musso G, Gambino R, Cassader M, Pagano G. Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med. 2011;43:617–49.CrossRefGoogle Scholar
  52. 52.
    Ballestri S, Zona S, Targher G, et al. Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta-analysis. J Gastroenterol Hepatol. 2016;31:936–44.CrossRefGoogle Scholar
  53. 53.
    Bugianesi E, Gastaldelli A, Vanni E, et al. Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms. Diabetologia. 2005;48:634–42.CrossRefGoogle Scholar
  54. 54.
    Cusi K. Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications. Gastroenterology. 2012;142:711–25.e6.CrossRefGoogle Scholar
  55. 55.
    Lomonaco R, Ortiz-Lopez C, Orsak B, et al. Effect of adipose tissue insulin resistance on metabolic parameters and liver histology in obese patients with nonalcoholic fatty liver disease. Hepatology. 2012;55:1389–97.CrossRefGoogle Scholar
  56. 56.
    Fain JN, Bahouth SW, Madan AK. TNF alpha release by the nonfat cells of human adipose tissue. Int J Obes Relat Metab Disord. 2004;28:616–22.CrossRefGoogle Scholar
  57. 57.
    Sabio G, Das M, Mora A, et al. A stress signaling pathway in adipose tissue regulates hepatic insulin resistance. Science. 2008;322:1539–43.CrossRefGoogle Scholar
  58. 58.
    Polyzos SA, Toulis KA, Goulis DG, Zavos C, Kountouras J. Serum total adiponectin in nonalcoholic fatty liver disease: a systematic review and meta-analysis. Metabolism. 2011;60:313–26.CrossRefGoogle Scholar
  59. 59.
    Cnop M, Welsh N, Jonas JC, Jorns A, Lenzen S, Eizirik DL. Mechanisms of pancreatic beta-cell death in type 1 and type 2 diabetes: many differences, few similarities. Diabetes. 2005;54(Suppl 2):S97–107.CrossRefGoogle Scholar
  60. 60.
    Horton JD, Goldstein JL, Brown MS. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest. 2002;109:1125–31.CrossRefGoogle Scholar
  61. 61.
    Postic C, Girard J. The role of the lipogenic pathway in the development of hepatic steatosis. Diabetes Metab. 2008;34:643–8.CrossRefGoogle Scholar
  62. 62.
    Ferre P, Foufelle F. Hepatic steatosis: a role for de novo lipogenesis and the transcription factor SREBP-1c. Diabetes Obes Metab. 2010;12(Suppl 2):83–92.CrossRefGoogle Scholar
  63. 63.
    Birkenfeld AL, Shulman GI. Nonalcoholic fatty liver disease, hepatic insulin resistance, and type 2 diabetes. Hepatology. 2014;59:713–23.CrossRefGoogle Scholar
  64. 64.
    Kumashiro N, Erion DM, Zhang D, et al. Cellular mechanism of insulin resistance in nonalcoholic fatty liver disease. Proc Natl Acad Sci U S A. 2011;108:16381–5.CrossRefGoogle Scholar
  65. 65.
    Cook JR, Langlet F, Kido Y, Accili D. Pathogenesis of selective insulin resistance in isolated hepatocytes. J Biol Chem. 2015;290:13972–80.CrossRefGoogle Scholar
  66. 66.
    Pirola CJ, Sookoian S. The dual and opposite role of the TM6SF2-rs58542926 variant in protecting against cardiovascular disease and conferring risk for nonalcoholic fatty liver: a meta-analysis. Hepatology. 2015;62:1742–56.CrossRefGoogle Scholar
  67. 67.
    Sookoian S, Pirola CJ. Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease. Hepatology. 2011;53:1883–94.CrossRefGoogle Scholar
  68. 68.
    Czupryniak L. Guidelines for the management of type 2 diabetes: is ADA and EASD consensus more clinically relevant than the IDF recommendations? Diabetes Res Clin Pract. 2009;86(Suppl 1):S22–5.CrossRefGoogle Scholar
  69. 69.
    Konner AC, Bruning JC. Toll-like receptors: linking inflammation to metabolism. Trends Endocrinol Metab. 2011;22:16–23.CrossRefGoogle Scholar
  70. 70.
    Cani PD, Amar J, Iglesias MA, et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes. 2007;56:1761–72.CrossRefGoogle Scholar
  71. 71.
    Miele L, Valenza V, La Torre G, et al. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology. 2009;49:1877–87.CrossRefGoogle Scholar
  72. 72.
    Ruiz AG, Casafont F, Crespo J, et al. Lipopolysaccharide-binding protein plasma levels and liver TNF-alpha gene expression in obese patients: evidence for the potential role of endotoxin in the pathogenesis of non-alcoholic steatohepatitis. Obes Surg. 2007;17:1374–80.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Cristiane A. Villela Nogueira
    • 1
  • Nathalie Carvalho Leite
    • 2
  1. 1.School of Medicine, Internal Medicine DepartmentFederal University of Rio de JaneiroRio de JaneiroBrazil
  2. 2.Clementino Fraga Filho University Hospital, Internal Medicine Division, Federal University of Rio de JaneiroRio de JaneiroBrazil

Personalised recommendations